Journal article icon

Journal article

Combined HDAC and BET inhibition enhances melanoma vaccine immunogenicity and efficacy

Abstract:

The combined inhibition of histone deacetylases (HDAC) and the proteins of the bromodomain and extraterminal (BET) family have recently shown therapeutic efficacy against melanoma, pancreatic ductal adenocarcinoma, testicular, and lymphoma cancers in murine studies. However, in such studies, the role of the immune system in therapeutically controlling these cancers has not been explored. We sought to investigate the effect of the HDAC inhibitor romidepsin (RMD) and the BET inhibitor IBET151, ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.4049/jimmunol.1800885

Authors


More by this author
Role:
Author
ORCID:
0000-0002-4318-7624
More by this author
Role:
Author
ORCID:
0000-0002-9995-1804
More by this author
Role:
Author
ORCID:
0000-0002-4498-7893
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
ORCID:
0000-0002-9694-2216
More from this funder
Grant:
K22 AI118421
P30 AI117943
R01 AI129797
UM1 AI126603
U19 AI096040
U19 AI128751
UM1 AI124377
Publisher:
American Association of Immunologists Publisher's website
Journal:
Journal of Immunology Journal website
Volume:
201
Issue:
9
Pages:
2744-2752
Publication date:
2018-10-22
Acceptance date:
2018-08-22
DOI:
EISSN:
1550-6606
ISSN:
0022-1767
Pmid:
30249811
Language:
English
Keywords:
Pubs id:
pubs:924218
UUID:
uuid:3618713c-a2af-4484-881b-fdabf9f9a3db
Local pid:
pubs:924218
Source identifiers:
924218
Deposit date:
2019-03-08

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP